Peritoneal Fluid and Serum Concentration of Interleukin-16 in Women with Endometriosis.
XM Zhang,J Lin,L Deng,ZY Chen,L Chen
DOI: https://doi.org/10.1111/j.0001-6349.2005.00679.x
2005-01-01
Acta Obstetricia Et Gynecologica Scandinavica
Abstract:Interleukin-16 (IL-16) is a homotetramer of 14-kDa subunits discovered in 1982 as a T-cell-specific chemoattractant factor. The gene of IL-16 is located on chromosome 15 (15q26.1) and unrelated to other interleukins or chemokines (1). IL-16, synthesized by CD4+ (T-helper/inducer T cells) and CD8+ (T-suppressor/cytotoxic T cells) T cells, has been shown to regulate the ratio between T-cell helper type 1 and T-cell helper type 2 (Th1/Th2). It also regulates the production of IL-1β, IL-6, IL-15, and tumor necrosis factor-α (TNF-α) in T cells and macrophages, all of which are involved in the pathogenesis of endometriosis 1-3). To date, the study of IL-16 concentrations in peritoneal fluid and sera of women with endometriosis has not been reported. We compared peritoneal fluid and serum IL-16 levels between women with and without endometriosis, the results of which are presented. Forty-four consecutive patients undergoing laparoscopic surgery from December 2001 through December 2002 at the Women's Hospital were recruited to the study. There were 22 healthy, fertile women undergoing tubal sterilization (designated normal group), and 22 with different stages of endometriosis confirmed by laparoscopic and histological examinations (designated endometriosis group). Clinical and operative findings were recorded. Endometriosis was graded according to the Revised American Fertility Society scoring system (1985). Venous blood was obtained preoperatively, and the serum was stored at −70 °C until analysis. Peritoneal fluid was obtained during the operation and similarly stored. Interleukin-16 analysis was by Human IL-16 ELISA kit (Human IL-16 BMS 248, Bender Medsystems, Vienna, Austria). Statistical analysis was by the Mann–Whitney U-test, unpaired T-test, and Spearman's rank correlation test. The study was approved by the Institutional Review Board of Women's Hospital, and informed consent was obtained from each participant before surgery. In women with endometriosis, the primary indication for surgery was infertility (n = 6), abdominal pain (n = 7), and pelvic mass (n = 9). Those in the normal group were parous and had no symptoms. There was no significant difference between the two groups with respect to age, previous abortion, and the phase of menstrual cycle at operation (Table I). The median concentrations of IL-16 in peritoneal fluid and sera were both lower in women with endometriosis than the normal, but the differences were not statistically significant (Table I). In all subjects, 25 were in the follicular phase (12 with endometriosis and 13 normal) and 19 in the luteal phase (10 with endometriosis and nine normal). There was no significant difference in IL-16 levels in peritoneal fluid or sera between phases of the cycle in either group. There was also no significant correlation between serum and peritoneal levels in either group. In women with endometriosis, the primary location of endometriosis was in the ovary (n = 17), the Pouch of Douglas (n = 4), and the lateral pelvic wall (n = 1). Four had stage 1 endometriosis, four had stage 2, nine had stage 3, and five had stage 4 endometriosis. There was no significant difference in IL-16 levels in either the peritoneal fluid or the sera between the different stages. Among those with endometriosis, there was no significant correlation between serum or peritoneal fluid IL-16 levels and a history of abortion, infertility, or abdominal pain. Interleukin-16 is a polypeptide proinflammatory cytokine that was originally described as a T-cell-specific chemoattractant factor (1). As a competence growth factor for CD4+ T cells and a regulator of cell-mediated immune mechanisms of Th1 type by inducing IL-2R, IL-16 has been shown to inhibit Th2-type cytokine including IL-4 and IL-5 production and activation-induced death of human T lymphocytes mediated by Fas ligand (4). It was suggested that IL-16 regulates the production of IL-1β, IL-6, IL-15, and TNF-α in human monocytes or macrophages in a concentration-dependent way (2). In addition, IL-16 also affects the levels of RANTES (regulated upon activation normal T-cell expressed and secreted), monocyte chemotactic protein-1 (MCP-1), and IL-2 (5). In this context, IL-16 could be involved in the pathogenesis of endometriosis, either by regulating cellular immune response to ectopic endometrial cells following retrograde menstruation, or by regulating the production of IL-1β, IL-2, IL-6, IL-15, RANTES, and TNF-α and MCP-1, which are involved in the pathogenesis of endometriosis 1-3, 5). However, our results showed that the concentrations of IL-16 in peritoneal fluid and peripheral blood were not significantly associated with the presence or the stage of endometriosis in either phase of the menstrual cycle. This implies that IL-16 may not play a part in the natural process of endometriosis. In conclusion, our results suggest that IL-16 is not involved in the pathogenesis of pelvic endometriosis. However, it must be emphasized that the concentrations of IL-16 with a high variability were detected in a small sample size, and it was possible that our study was relatively too small to detect a difference. Therefore, the small sample size necessitates that this finding be validated in a larger study. Further work is needed to explore the use of this potent molecule in animal and in vitro models of endometriosis. We thank Dr Allan Chang from Mater Health Services, Brisbane, Australia, for assisting with our English.